Google’s AI Helped Doctors Prepare for Patient Visits

Google’s Medical AI Could Make Doctor Visits More Useful

Google’s medical AI chatbot just completed a real-world test with 98 patients.

In a study published in The Lancet, patients spoke with Google's AMIE chatbot before visiting a primary care clinic. Doctors monitored the conversations, and none required intervention under the study’s safety rules.

The results look promising.

AMIE’s suggested diagnoses matched doctors’ final diagnoses 90% of the time, while 75% of clinicians said its summaries helped them prepare for appointments.

What interests me most is the preparation.

Doctors often have limited time to understand a patient’s symptoms during an appointment, and having that information ready on a screen beforehand could make those conversations more focused.

The study is small, and physician supervision was built into the process, so it doesn't establish whether the system is safe for wider independent use.

Still, the findings suggest a practical role for medical AI in gathering patient information before consultations.

Could patients eventually spend less time explaining their symptoms and more time discussing treatment?

Manus Raises $500M After China Blocks Meta Acquisition

Manus just raised over $500 million, months after Chinese regulators forced it to abandon a $2 billion acquisition by Meta.

The AI startup, known for its autonomous agents, secured funding from Boyu Capital, IDG Capital, Tencent, and other investors. It had reportedly been seeking a $4 billion valuation, although the final figure remains undisclosed.

That's a significant recovery.

China blocked the Meta deal over concerns about losing domestic AI talent, leaving Manus to resume independent operations after relocating its team to Singapore.

What stands out to me is that investors are still willing to commit hundreds of millions to Manus despite the regulatory uncertainty surrounding its future.

The company is also expanding beyond its original chatbot with Cue, an app that gives AI agents their own email addresses, phone numbers, and digital wallets to complete tasks and make payments.

That makes the next phase interesting.

With a possible Hong Kong IPO under consideration, Manus now has to prove that its products can sustain the investor confidence that survived its failed Meta acquisition.

Can it build a major AI business while navigating China's restrictions on foreign ownership?

OpenAI’s Revenue Numbers Are Testing Investor Confidence

OpenAI just gave investors a reason to question how much AI companies are worth.

The company reported $50 billion in annualized revenue, well below the $68 billion figure circulated last month. The higher number included revenue from partners, which makes the difference in reporting important.

Investors reacted quickly.

Nvidia fell 3%, Oracle dropped nearly 6%, and CoreWeave lost almost 8% during Thursday’s trading session.

The concern makes sense. OpenAI is still growing rapidly, with enterprise revenue run rate up 107% in the third quarter, but its $852 billion valuation leaves little room for investors to misunderstand the numbers.

I think the bigger issue is how closely the market has tied AI infrastructure valuations to expectations about OpenAI’s future spending.

A revenue clarification at one company was enough to send several major chip and cloud stocks lower within hours.

With OpenAI preparing for a possible 2027 IPO, investors may start demanding clearer financial disclosures across the industry.

How much of today's AI valuations depends on revenue expectations that still need closer scrutiny?

Prohuman team

Free Guides

Explore our free guides and products to get into AI and master it.

All of them are free to access and would stay free for you.

Feeling generous?

You know someone who loves breakthroughs as much as you do.

Share The Prohuman it’s how smart people stay one update ahead.